High HMGN1 levels drive leukemia in Down syndrome
Nature Genetics
April 21, 2014
A genetic cause of the link between Down syndrome and B cell acute lymphoblastic leukemia (B-ALL) in both mice and human cells is reported in a paper published online this week in Nature Genetics. The study identifies a promising drug target to treat B-ALL in Down syndrome.
People with Down syndrome are at a 20-fold risk of developing a type of B-ALL, an aggressive cancer of the white blood cells. David Weinstock and colleagues found that having three copies of a small region of 31 genes on chromosome 21 was sufficient to drive the cancer. Using a combination of experiments in mice and human cells, they found that increased levels of a specific protein, HMGN1, turns on the group of genes needed for the cancer to spread. The increase in HMGN1 levels was specific to Down syndrome B-ALL, but not other types of ALL.
The authors speculate that drugs that inhibit HMGN1 could prove useful for treating B-ALL in Down syndrome patients.
doi: 10.1038/ng.2949
Research highlights
-
Sep 20
Cell biology: Endocannabinoid system may be involved in human testis physiologyScientific Reports
-
Sep 19
Health: Birth mode linked to microbiome disruptionNature
-
Sep 18
Ecology: Stress-resistant corals maintain heat tolerance under cooler temperaturesNature Communications
-
Sep 12
Stem cells: Modelling early human embryo developmentNature
-
Sep 11
Zoology: New electric eel species produces quite a shockNature Communications
-
Sep 11
Evolution: A virtual skull of modern humans’ last common ancestorNature Communications
